.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
Medtronic
UBS
Accenture
Cantor Fitzgerald
Fuji
Queensland Health
Moodys
Chubb

Generated: September 22, 2017

DrugPatentWatch Database Preview

VIOXX Drug Profile

« Back to Dashboard

Which patents cover Vioxx, and when can generic versions of Vioxx launch?

Vioxx is a drug marketed by Merck and is included in two NDAs. There is one patent protecting this drug.

This drug has thirty-seven patent family members in thirty-one countries.

The generic ingredient in VIOXX is rofecoxib. There are two drug master file entries for this compound. Additional details are available on the rofecoxib profile page.

Summary for Tradename: VIOXX

Patents:1
Applicants:1
NDAs:2
Bulk Api Vendors: see list71
Clinical Trials: see list6
Patent Applications: see list6,179
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIOXX at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-001May 20, 1999DISCNNoNo► Subscribe► SubscribeY► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-001May 20, 1999DISCNNoNo► Subscribe► SubscribeY► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-002May 20, 1999DISCNNoNo► Subscribe► SubscribeY► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-003Feb 25, 2000DISCNNoNo► Subscribe► SubscribeY► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-002May 20, 1999DISCNNoNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIOXX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-001May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-001May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-001May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-002May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-002May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-002May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-001May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-002May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-001May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-003Feb 25, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIOXX

Country Document Number Estimated Expiration
Czech Republic9803738► Subscribe
Iceland4891► Subscribe
Brazil9709097► Subscribe
Australia3004997► Subscribe
Eurasian Patent Organization001596► Subscribe
United Kingdom9612063► Subscribe
China1140267► Subscribe
Hong Kong1021623► Subscribe
Norway985342► Subscribe
Peru66998► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Cantor Fitzgerald
Chubb
Harvard Business School
Fuji
Cipla
Baxter
Julphar
Johnson and Johnson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot